Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Evoke Pharma (EVOK) Receivables (2020 - 2025)

Historic Receivables for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to $3.2 million.

  • Evoke Pharma's Receivables rose 5774.82% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 5774.82%. This contributed to the annual value of $2.4 million for FY2024, which is 25960.14% up from last year.
  • Latest data reveals that Evoke Pharma reported Receivables of $3.2 million as of Q3 2025, which was up 5774.82% from $2.9 million recorded in Q2 2025.
  • Evoke Pharma's Receivables' 5-year high stood at $3.2 million during Q3 2025, with a 5-year trough of $127795.0 in Q1 2021.
  • In the last 5 years, Evoke Pharma's Receivables had a median value of $687302.0 in 2023 and averaged $1.2 million.
  • Per our database at Business Quant, Evoke Pharma's Receivables skyrocketed by 116632.49% in 2021 and then soared by 772.03% in 2023.
  • Evoke Pharma's Receivables (Quarter) stood at $295193.0 in 2021, then skyrocketed by 111.67% to $624832.0 in 2022, then rose by 7.72% to $673071.0 in 2023, then skyrocketed by 259.6% to $2.4 million in 2024, then surged by 31.82% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, $2.9 million for Q2 2025, and $2.5 million during Q1 2025.